Clinical & Scientific

Sōlaria Biō’s new study validates a microbe-based medical food, Bōndia™, offering a novel, science-backed approach to bone loss for millions of women.

With impressive preliminary sales and key pipeline updates, Mirum Pharmaceuticals' upcoming earnings call will focus on its strategy for sustained growth in 2026.

With $3.7M in new capital, Sift Biosciences is developing a novel immunotherapy to awaken the body's memory T cells against hard-to-treat diseases.

A novel drug candidate targeting treatment-resistant kidney disease has begun its long journey through clinical trials, signaling a major strategic push.

As Adagene presents at key conferences, its SAFEbody tech and lead drug muzastotug draw focus amid a strategic push for funding and partnerships.

A new FDA approval allows a lung cancer therapy to be given just once a month, a major shift promising to reduce clinic time and improve quality of life.

A new five-year deal will leverage patient-derived stem cells and AI to revolutionize the hunt for Alzheimer's cures, aiming to bridge a critical gap.

A new partnership aims to manufacture a life-saving gene therapy for NKH, a devastating rare disorder, driven by a family's relentless advocacy.

Bausch Health heads to a key finance conference to address investor concerns over its massive debt, upcoming patent cliffs, and future strategic direction.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

A new therapy for a rare brain cancer is one step closer to patients after the FDA accepted tirabrutinib for accelerated review, offering hope where few options exist.

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

With a $15 million funding boost, Nasus Pharma is accelerating its powder-based intranasal epinephrine, NS002, challenging the EpiPen's dominance.

With strong Phase 1 data and key FDA backing, Trethera's TRE-515 is advancing as a 'pipeline-in-a-product' for a wide range of diseases.

Nektar Therapeutics secures a massive $400M offering, signaling strong investor faith in its lead drug, rezpegaldesleukin, for autoimmune diseases.

Laurie Ann Goldman, the branding guru who built SPANX, is now CEO of Audien Hearing. Can she make affordable hearing aids a mainstream wellness product?

Kincell Bio and RegCell partner to bring a groundbreaking, non-gene-edited Treg cell therapy for autoimmune diseases from the lab to clinical trials.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.

A new German partnership aims to create variant-ready, room-temperature stable vaccines, moving beyond the limits of first-generation mRNA technology.

Ernexa Therapeutics secures crucial funding for its cancer therapy pipeline, but the dilutive offering sends its stock plunging more than 50%.